Tongue hyperpigmentation following idarubicin-based induction therapy in adverse-risk acute myeloid leukemia
Satish Kumar Basattikoppalu Puttegowda, Pooja Anjanappa, Mohith Shivaramu, Manoj Holenarasipura Ravindra
Adichunchanagiri University
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Anthracycline-derived antibiotics are prescribed frequently for treating patients diagnosed with acute myeloid leukemia (AML) and are notable for their association with mucositis and myelosuppressive properties; however, chemotherapy-induced oral hyperpigmentation resulting from the use of anthracycline antibiotics is rare and poorly documented, especially for idarubicin. A 29-year-old female presenting with fever and anemia along with bleeding manifestations was subsequently diagnosed with AML (FAB M4) based on laboratory findings of a hemoglobin level of 8.9 g/dL, a platelet count of 12 × 10 9 /L, and leukocytosis. The diagnosis was confirmed by bone marrow examination, which also identified FLT3-ITD and WT1 mutations through molecular studies, indicating that she had an European Leukemia Net 2017 risk classification of high risk. Induction chemotherapy was given using a 5 + 3 regimen (idarubicin + cytarabine). Day 19 after beginning therapy, the patient developed diffuse hyperpigmentation of the lesion, which was asymptomatic and showed no evidence of ulceration and infection. According to the Naranjo scale, the association between the drug and adverse reaction is possible. The patient was treated with topical triamcinolone but was allowed to continue the chemotherapy treatment without interruption. Idarubicin-associated tongue hyperpigmentation is a rare, benign, and reversible adverse effect. Recognition of this entity is important to avoid misdiagnosis and unnecessary modification of potentially life-saving chemotherapy.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Chemotherapy-related skin toxicity
Acute Myeloid Leukemia Research · Oral health in cancer treatment